Literature DB >> 1526330

Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus.

M R Taskinen1.   

Abstract

In people with diabetes, the concentration of an individual lipoprotein or apolipoprotein can be highly variable and is totally different in the two major forms of the disease. Alterations in the concentrations of major lipids and lipoproteins are well characterized in both IDDM and NIDDM. In general, the lipoprotein pattern is antiatherogenic in individuals with IDDM who are treated and have optimal glycemic control. In contrast, NIDDM is associated with atherogenic changes of serum lipids and lipoproteins regardless of the mode of treatment. In people with both types of diabetes, the distribution of apoE phenotype seems to be similar to that in nondiabetic populations. IDDM patients with microalbuminuria show atherogenic changes of lipoproteins and have elevated levels of Lp(a), which is a risk factor of coronary artery disease. Whether glycemic control influences the concentration of Lp(a) is still an open question. An important issue is that the concentration of a lipoprotein can be normal without excluding compositional abnormalities that are potentially atherogenic. Such alterations are present in people with both IDDM and NIDDM. Consequently, it has been questioned whether the target values to start treatment should be lower in diabetic than in nondiabetic populations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526330     DOI: 10.2337/diab.41.2.s12

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  25 in total

1.  Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats.

Authors:  P S Babu; K Srinivasan
Journal:  Mol Cell Biochem       Date:  1997-01       Impact factor: 3.396

2.  Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides.

Authors:  S Lahdenperä; M Syvänne; J Kahri; M R Taskinen
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 3.  New frontiers in the treatment of diabetic dyslipidemia.

Authors:  Shu-Yi Wang; Ming-Chia Hsieh; Shih-Te Tu; Chieh-Sen Chuang
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 4.  Why do some patients with type 1 diabetes live so long?

Authors:  Larry A Distiller
Journal:  World J Diabetes       Date:  2014-06-15

5.  Association of lipoprotein lipase (LPL) single nucleotide polymorphisms with type 2 diabetes mellitus.

Authors:  Yoon Shin Cho; Min Jin Go; Hye Ree Han; Seung Hun Cha; Hung Tae Kim; Haesook Min; Hyoung Doo Shin; Chan Park; Bok Ghee Han; Nam Han Cho; Chol Shin; Kuchan Kimm; Bermseok Oh
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

Review 6.  Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

Authors:  S J Cleland; B M Fisher; H M Colhoun; N Sattar; J R Petrie
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

Review 7.  Vascular calcification in diabetes: mechanisms and implications.

Authors:  Janet K Snell-Bergeon; Matthew J Budoff; John E Hokanson
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 8.  Regulation of signal transduction by HDL.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  J Lipid Res       Date:  2013-05-18       Impact factor: 5.922

9.  Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats.

Authors:  Bhoomika R Goyal; Pravin Mesariya; Ramesh K Goyal; Anita A Mehta
Journal:  Mol Cell Biochem       Date:  2008-04-19       Impact factor: 3.396

10.  Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study.

Authors:  John Guy; Lorraine Ogden; R Paul Wadwa; Richard F Hamman; Elizabeth J Mayer-Davis; Angela D Liese; Ralph D'Agostino; Santica Marcovina; Dana Dabelea
Journal:  Diabetes Care       Date:  2008-12-17       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.